Background: Serotonin-noradrenaline reuptake inhibitors (SNRI) are widely used in medical
practice. Their discontinuation has been associated with a wide range of symptoms. The aim …

Antidepressant–placebo response-differences (RDs) in controlled trials have been
declining, potentially confounding comparisons among older and newer drugs. For clinically …

Background Although pharmacological and psychological interventions are both effective for
major depression, in primary and secondary care settings antidepressant drugs remain the …

Introduction: Major depressive disorder (MDD) remains a major public health concern, and
one that continues to suffer an incompletely-met need for effective and acceptable …

Introduction: Selective serotonin and norepinephrine reuptake inhibitors (SNRI) are among
the most prescribed antidepressants, and dose escalation is a frequently applied strategy …

Even though noradrenaline has been recognized as one of the key neurotransmitters in the
pathophysiology of major depression (MD), noradrenergic compounds have been less …

Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …

Objectives: To evaluate the short-term efficacy and safety of desvenlafaxine (25–50 mg/d)
compared with placebo in children and adolescents with major depressive disorder (MDD) …

Background In an effort to establish the lowest effective dose of desvenlafaxine
(administered as desvenlafaxine succinate), we assessed the efficacy, safety, and …

This randomized, open label, prospective, observational study compared clinical efficacy,
safety alongwith plasma BDNF levels in outpatients of depression treated with fluoxetine …